and retrospectively analysed, providing 141 dose measurements for all the MOSkins. Measured and calculated contributions by each single catheter were quantified separately. Discrepancies were plotted depending on weighted average polar angles and distances between MOSkins and source, and a linearly fitting CF was calculated.
Material and Methods:
An MC based dose calculation engine for RSBT has been developed and coupled with a columngeneration optimizer. At every iteration of the optimization loop, the column-generation process solves a pricing problem to determine the best dwell position and shield angle combination to add to the treatment plan, resulting in the best possible plan with the shortest treatment time. As a source model, the microSelectron-v2 source geometry was selected and placed inside a cylindrical platinum shield with a diameter of 1.8 mm and 3.0 mm for interstitial and intracavitary cases, respectively. An emission window coinciding with the active core of the source was created by removing half (180º) of the wall of the shield. For an interstitial prostate case, RSBT plans were generated only using Gd-153 as a source due to the extreme limitations on shield size in interstitial catheters. For the intracavitary GYN case, both Gd-153 and Se-75 plans were generated. All RSBT plans were compared with conventional HDR BT. Only the original dwell positions used in conventional BT were sampled to create the RSBT plans.
Results: RSBT plans resulted in a considerable reduction in both rectum and bladder doses without sacrificing target coverage for the prostate case. With 95% of the PTV volume receiving over 15 Gy, only 40% of the rectum volume received more than 2 Gy for the Gd-153 RSBT case,as opposed to 85% for the unshielded Ir-192 conventional plan.
For the GYN patient, the median rectum dose was 2.4 Gy, 3.2 Gy and 3.45 Gy for Gd-153 RSBT, Se-75 RSBT and unshielded Ir-192, respectively, with an identical target coverage. The Gd-153 case was also able to reduce the dose to the bladder by 41%.
Conclusion:
The development of the first MC-based TPS devoted to RSBT has been successfully accomplished. For the prostate case, a significant dosimetric improvement was achieved over conventional BT using Gd-153 with optimized shield angles. For the GYN case, the improvement was diminished by the central position of the conventional BT dwell positions within the target volume. RSBT allows the placement of dwell positions much closer to normal tissue, which will yield superior dose distributions when properly optimized. RSBT will decrease normal tissue toxicity and allow for tailoring treatments to each individual patient by treating all parts of the tumour without over-irradiation of large regions of normal tissues. Purpose or Objective: Acute dysphagia is a frequently observed toxicity during concurrent chemo-radiation (CRT) or high-dose radiotherapy (RT) for lung cancer. This toxicity can lead to hospitalizations, treatment interruptions and consequently reduce chances of survival. Models to predict acute dysphagia are available. However, these models were based on limited amounts of data and the performance of these models needs improvements before implementation into routine practice. Furthermore, Bayesian network models are shown to perform better than conventional modeling techniques on datasets with missing values, which is a common problem in routine clinical care. In this work, we train a Bayesian network model on a large clinical datasets, originating predominantly from routine clinical care, to accurately predict acute dysphagia in NSCLC patients during and shortly after (C)RT.
Material and Methods:
Clinical data from 1250 inoperable NSCLC patients, treated with radical CRT, sequential chemoradiation or RT alone were collected. The esophagus was delineated using the external esophageal contour from the cricoid cartilage to the GE junction. A Bayesian network model was developed to predict severe acute dysphagia ( ≥ Grade 3 according to the CTCAEv3.0 or v4.0). The model utilized age, mean esophageal dose, timing of chemotherapy and N-stage to make predictions. Variable selection and structure learning was done using the PC-algorithm. The model was trained on data from 1250 patients. The model's performance was assessed internally and on an external validation set (N=218) from the United Kingdom. Model discriminative performance was expressed as the Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC). ROCs were compared using the method proposed by DeLong and colleagues. Model performance was also assessed in terms of calibration. Calibration refers to the agreement between the observed frequencies and the predicted probabilities and is expressed as the coefficient of determination (r2).
Results:
One-hundred forty patients (11,2%) developed acute dysphagia (≥ Grade 3 according to the CTCAEv3.0 or v4.0). The model was first validated internally, by validating on the training cohort (N=1250, AUC = 0.77, 95% CI: 0.7325-0.8086, r2 = 0.99). Subsequently, the model was externally validated on a UK dataset (N = 218, AUC = 0.81, 95% CI: 0.74-0.88, r2 = 0.64). The ROC curves were not significantly different (p = 0.28).
